In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback